A retrospective analysis of the use of loteprednol etabonate ophthalmic suspension 0.5% following canaloplasty

BACKGROUND: While loteprednol etabonate (LE) suspension 0.5% is approved for the treatment of postoperative ocular inflammation, there have been no reported studies of its use in glaucoma patients undergoing canaloplasty. METHODS: This was a retrospective medical chart review conducted at a single U...

Descripción completa

Detalles Bibliográficos
Autor principal: Khaimi, Mahmoud A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5815503/
https://www.ncbi.nlm.nih.gov/pubmed/29491705
http://dx.doi.org/10.2147/OPTH.S153912

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5815503/
https://www.ncbi.nlm.nih.gov/pubmed/29491705
http://dx.doi.org/10.2147/OPTH.S153912

Ejemplares similares